Regeneron Pharmaceuticals Inc REGN:NASDAQ

Last Price$597.00NASDAQ Previous Close - Last Trade as of 3:59PM ET 6/05/20

Today's Change-1.54(0.26%)
Bid (Size)$590.01 (1)
Ask (Size)$596.00 (1)
Day Low / High$578.43 - 600.14
Volume1.3 M

Regeneron Grants Zai Lab Rights to Develop, Commercialize Lymphoma Drug in China, Hong Kong, Taiwan, Macau

6:43AM ET 4/08/2020 MT Newswires
Regeneron Pharmaceuticals (REGN), a US biotech firm, and Zai Lab (ZLAB), a Chinese commercial-stage biopharmaceutical company, said Wednesday that Zai Lab has obtained rights to develop and commercialize Regeneron's lymphoma drug, REGN1979, in mainland China, Hong Kong, Taiwan and Macau.

Regeneron will receive a $30 million upfront payment and is eligible to receive up to $160 million in additional regulatory and sales milestones, the companies said in a statement.

The Regeneron-Zai Lab collaboration will also support enrollment of regional patients into Regeneron's global trials assessing REGN1979 in B-cell non-Hodgkin lymphoma (B-NHL), the companies said.

REGN1979 is designed to trigger tumor killing by linking and activating a cytotoxic T-cell to a lymphoma cell, according to the statement.

Price: 501.51, Change: -2.76, Percent Change: -0.55